MedTrace Logo

Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

NCT04454398 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-01-08

No results posted yet for this study

Summary

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19

Conditions

Interventions

BIOLOGICAL

COVI-GUARD

COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein

OTHER

Standard of Care

Standard of Care as determined by the Investigator

DRUG

Placebo

Diluent

Sponsors & Collaborators

  • Sorrento Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mike Royal, MD · Sorrento Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-01-31
Completion
2021-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04454398 on ClinicalTrials.gov